
Fulgent Genetics reiterated full year 2026 revenue guidance of approximately $350.0 million. The company updated its Non-GAAP loss to approximately $46.0 million, or $(1.59) per share, and expects $636.0 million in cash and investments.
Bullish
Fulgent Genetics executed a $40.1 million stock repurchase in Q1 2026 and advanced its therapeutic development pipeline. The company maintains a strong cash position and expects gross margins to improve in the second half.
Bearish
Fulgent Genetics experienced declining Q1 2026 revenue to $71.1 million and increased GAAP losses to $24.8 million, with gross margins compressing to 30.2%. The company also faces customer concentration and tax refund timing risks.